Beyond Air’s Beyond Cancer reports updated data from Phase 1 UNO trial

Beyond Cancer, a subsidiary of Beyond Air (XAIR), announced updated follow-up data from its Phase 1 UNO trial, which are being presented at the American Association for Cancer Research, AACR, Annual Meeting 2026 in San Diego, California. The Phase 1 trial was a clinical proof-of-concept trial that assessed the intratumoral administration of UNO in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions. As of February 2, 2026, six of ten patients remain alive between 22 to 40 months following a single UNO injection. While the study was not designed to assess efficacy and lacks a control arm, these observations may suggest prolonged survival in this heavily pretreated population. Interpretation of these results is limited by the small sample size and early-stage design. Two patients with triple negative breast cancer continue to demonstrate no evidence of disease, based on available imaging, testing, and clinical examinations. Treatment demonstrated a generally favorable safety and tolerability profile, with most treatment-related adverse events predominantly Grade 1 or Grade 2.